Pancreatic Cell News 9.36 September 11, 2018 | |
| |
TOP STORYResearchers found that subdiaphragmatic vagotomy in LSL-Kras+/G12D;Pdx1-Cre (KC) mice accelerated pancreatic cancer development, whereas treatment with the systemic muscarinic agonist bethanechol restored the normal KC phenotype, thereby suppressing the accelerated tumorigenesis caused by vagotomy. [Cancer Discov] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISNovel Polysaccharide H-1-2 from Pseudostellaria heterophylla Alleviates Type 2 Diabetes Mellitus H-1-2 significantly inhibited hypoxia and up-regulated Sirt1 expression in EndoC-βH1 cells. Accordingly, H-1-2 enhanced glucose-stimulation insulin secretion and improved blood glucose and lipid profiles in type 2 diabetes mellitus cells, and elevated glucose and insulin tolerance simultaneously. [Cell Physiol Biochem] Full Article The authors evaluated the effects of cannabinoid ligands on Ca2+ signaling in acinar cells. They found that the eight CB2R agonists tested inhibited ACh-induced Ca2+ oscillations. The endogenous cannabinoid substance, 2-arachidonoylglycerol, did not show an inhibitory effect on Ca2+ oscillations. [Acta Pharmacol Sin] Abstract Researchers showed that decellularized (DC) pancreatic scaffolds were successfully produced from type 1 diabetic mellitus (T1DM) and T2DM pancreas and maintained their extracellular matrix composition, 3D ultrastructure and various cytokines. All of the pancreatic scaffolds were sufficiently cytocompatible and were able to support proliferation and adhesion of human umbilical vein endothelial cells and MIN-6 β cells. [Artif Organs] Abstract PANCREATIC CANCERScientists identified phosphatidylinositol phosphate kinase PIP5K1A as a KRAS-specific interactor and showed that PIP5K1A bound to a unique region in KRAS. PIP5K1A depletion specifically reduced oncogenic KRAS signaling and proliferation, and sensitized pancreatic cancer cell lines to a MAPK inhibitor. [Nat Commun] Full Article Investigators showed that pancreatic stellate cells (PSCs) in vitro expressed higher PD-L1 mRNA and protein levels compared to the levels present in pancreatic ductal adenocarcinoma cells. They showed that inhibitors targeting bromodomain and extra-terminal proteins and BRD4 knockdown decreased interferon-γ-induced PD-L1 expression in PSCs. [Sci Rep] Full Article A Novel Prognostic Marker and Immunogenic Membrane Antigen: Prohibitin (PHB) in Pancreatic Cancer PHB was generally expressed in eight tested pancreatic ductal adenocarcinoma (PDAC) cell lines. PHB was increased in PDAC patient sera. siRNA-PHB decreased cell growth, migration and invasion. PHB overexpression resulted in the opposite effects. [Clin Transl Gastroenterol] Full Article Protein arginine methyltransferase 1 (PRMT1) was downregulated in two pancreatic cancer (PC) cell lines and human tumors. PRMT1 downregulation in PANC-1 and SW1990 cells significantly suppressed cancer proliferation and invasion in vitro and xenograft in vivo. However, PRMT1 overexpression did not have function impact in PC cells. [IUBMB Life] Abstract Scientists demonstrated that upregulation of Dnmt1 increased β-cell proliferation. In vivo, they showed that levels of serum insulin were increased in RIP-TVA mice with RCASBP-Dnmt1 infection compared with wild-type control mice with RCASBP-Dnmt1 infection. [Cancer Gene Ther] Abstract Interferon gamma (IFN-γ) treatment decreased the expression and secretion of CXCL8 in BxPC-3 PC cells, suppressed the proliferation and migration of these cells, and enhanced their apoptosis, as determined by increased levels of cleaved caspase-8 and Bax together with reduced expression of Bcl-2. These effects were abolished by overexpression of CXCL8. [J Interferon Cytokine Res] Abstract Subscribe to one of our other 19 science newsletters such as Hepatic Cell News & Intestinal Cell News. | |
| |
REVIEWSBiomarkers in Islet Cell Transplantation for Type 1 Diabetes Islet transplantation, an important approach to achieve insulin independence for individuals with type 1 diabetes, is limited by the lack of accurate biomarkers to track beta-cell death post islet infusion. The authors discuss existing and recently described biomarkers. [Curr Diab Rep] Full Article Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
INDUSTRY NEWSADOCIA announced positive pharmacodynamic and safety topline results from the Phase I study of BioChaperone® Pramlintide Insulin, the ready-to-use co-formulation of pramlintide and human insulin. [ADOCIA] Press Release ImmusanT Expands Platform to Type 1 Diabetes with Investment from JDRF T1D Fund ImmusanT, Inc. announced that it has received an investment from the JDRF type 1 diabetes (T1D) Fund. With the funds, ImmusanT plans to accelerate the translation of insights and clinical experience gained from its celiac disease program to the development of a novel vaccine candidate for T1D. [ImmusanT, Inc.] Press Release The Familial Chylomicronemia Syndrome Foundation Implores FDA to Approve Much Needed Therapy The Familial Chylomicronemia Syndrome (FCS) Foundation, the only patient group in the United States focused on supporting patients and families living with FCS, is urging the U.S. FDA to approve WAYLIVRA and to provide commercial access to patients who are desperately in need. [The FCS Foundation (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSJuvenile Diabetes Cure Alliance Petition Demands an Increase in T1D Cure Research Funding Continuing their efforts to push major diabetes organizations to increase cure research funding for type 1 diabetes, the Juvenile Diabetes Cure Alliance launched its 4th Annual More for a T1D Cure Petition. The petition aims to send an important message to diabetes charities: Financial supporters want to see more dollars spent on cure research. [Juvenile Diabetes Cure Alliance (Business Wire, Inc.)] Editorial Advocate for Women in Science Wins Prestigious Lasker Award Pioneers in anaesthesiology, DNA structure and RNA biology are this year’s Lasker Awards recipients. The annual prize rewards achievements in biomedical research and is often considered a precursor to the Nobel. [Nature News] Editorial Pivotal CRISPR Patent Battle Won by Broad Institute The US Court of Appeals for the Federal Circuit awarded the pivotal intellectual property to the Broad Institute of Cambridge, Massachusetts, upholding a previous decision by the US Patent and Trademark Office. The decision spells defeat for a team of inventors that includes molecular biologist Jennifer Doudna University of California, Berkeley. [Nature News] Editorial Peer Reviewers in Developing Nations Are Underrepresented, Report Suggests Combined, scientists spend nearly 70 million hours peer reviewing manuscripts for scholarly journals every year, a new report says. But too much of the onus rests on researchers in wealthy countries, according to the report by the company Publons—based in London and Wellington—which enables researchers to track and claim credit for the peer reviews they perform. [ScienceInsider] Editorial
| |
EVENTSNEW Gordon Research Conference: Pancreatic Diseases Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Assistant Professor – Biomedical Sciences (New York Institute of Technology) Scientists – Diabetes Research (Qatar Biomedical Research Institute) Caspar Wistar Fellows – Cancer Biology (The Wistar Institute) Postdoctoral Researcher – Diabetes Research (UC San Diego School of Medicine) Postdoctoral Associate – Biology of the Pancreas and Diabetes (University of Minnesota) Assistant/Associate/Full Professor – Diabetes & Neuroscience (Indiana University School of Medicine) Postdoctoral Position – Beta Cell Research (Helmholtz Zentrum Munchen) Postdoctoral Positions – Immunology of Diabetes (Cochin Institute) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|